Cohance Lifesciences reports a 23% fall in revenue amid timing and demand challenges, yet highlights strategic wins and pipeline progress that could underpin future recovery and expansion.
Cohance Lifesciences said its latest quarter was weighed down by timing shifts and weaker demand in parts of the portfolio, with consolidated revenue falling 23% from a year earlier in the three months to June 30, 2026. The Mumbai-listed company’s pharma CDMO revenue dropped 38.7%, while adjusted EBITDA margin narrowed to 2.2% as lower sales, poor operating leverage and the consolidation of NJ Bio dragged on profitability, according to the company’s earnings-call summary.
Management pointed to a mixed operating picture. The specialty chemicals business fell 34.7% year on year, mainly because several AgChem CDMO products were always expected to be weighted towards the second half. The formulation arm also underperformed after an API production delay, softer demand for a mature product and a customer-led change in packaging configuration, while NJ Bio reported an adjusted EBITDA loss of $328 million and weaker-than-expected revenue.
Even so, the company highlighted several signs of momentum. It said it had secured a meaningful restocking order for a commercial molecule, improving delivery visibility for the fourth quarter of fiscal 2027 and fiscal 2028. A customised ADC payload order remains on track for a second-quarter delivery, and shipments on an oligonucleotide programme began in the first quarter. Cohance also said it completed multiple customer audits across its pharma CDMO and API sites without any critical findings.
The longer-term pipeline remains central to the investment case. Earlier reporting on the company’s earnings calls showed it had deepened ties with large global innovators, carried a late-stage pipeline that included Phase III programmes and won a commercial key starting material opportunity in specialty chemicals expected to begin supplying in the second half of fiscal 2027. On the latest call, executives said the nucleic acid business has more room to scale, while API Plus remains the core earnings engine, supported by differentiated products, strong customer relationships and new filings planned for fiscal 2027.
Risks remain, however. Cohance disclosed a Form 483 with five observations from the US Food and Drug Administration after an inspection of its Pasha Milan facility, although it said none related to data integrity. The company also said remediation at its Nacharam site is still an immediate priority. Management described its $1 billion fiscal 2030 sales goal as an aspiration rather than a firm commitment for now, while adding that margin recovery is likely to be skewed towards the second half of the year.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
